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ABSTRACT 
Title: Unipharma, S.A.: Creating value delivering pharmaceutical drugs 
Author: Manuel Marinheiro Coimbra  
It was early January 2008 when the company finally started operating. The result of 
several months of planning, after-work hours and sleepless nights all came down to that 
phone call. On the other side, speaking, was the sales director of one of the most 
important hospitals in Portugal. Pedro Azevedo could not be more pleased. 
Unipharma, S.A. is a Portuguese company that operates in the wholesaling business of 
the pharmaceutical industry. Due to its innovative business plan focused on the 
unlicensed, off-label and orphan drugs, the company has been consistently growing year 
after year, being the internationalization process a not so far away reality. 
The aim of this case study is to describe the creation process of the company from the 
moment where the opportunity was identified until the present day. It also includes an 
overview of the industry, as well as all the relevant data regarding the company’s 
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CHAPTERS 
1. CASE STUDY 
1.1 Introduction 
 “Any way the wind blows...” whispered Pedro Azevedo in duet with Freddie Mercury 
as Queen’s Bohemian Rhapsody ended playing once more in his car sound system. It 
was just another journey between Lisbon and Oporto. Pedro would never get tired of 
that CD. This was the perfect closure for a week of tough decisions and the next song 
could not be more suitable. The show would really go on… 
Pedro has been working in the pharmaceutical industry for 25 years now. Back in 2006, 
he decided he would improve the way hospitals make business regarding unlicensed 
drugs
1
; and so he did. 
After two years of intensive market research and sleepless hours the project was finally 
on. The operations started under the umbrella of a large British corporation which later 
dropped out in order to become a competitor. Today, with four years of activity, 30% of 
market share and eight drugs amongst the most sold within the category, Portugal does 







                                                   
1
The term “unlicensed drug” is related to the marketing authorization. It should be referred that, in this 
case, being “unlicensed” has nothing to do with drugs undergoing clinical trials or prepared 
extemporaneously. These “unlicensed drugs” are used in other countries with proven results and, in order 
to be commercialized in Portugal, they have to go through an exhaustive process of evaluation conducted 
by INFARMED, I.P. 
 
 
This case describes a real life event. Proprietary data has been disguised and despite being real, the names 
of characters and companies are fictitious in order to preserve confidentiality. 
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1.2 The Pharmaceutical Industry 
The pharmaceutical industry is the responsible for the discovering, production and 
marketing of drugs licensed for use as medications, for humans or animals, as well as of 
medical devices. It is one of the most profitable and influential business sectors in the 
world, being subjected to high regulated environment where companies must follow a 
variety of laws and regulations regarding the patenting, testing and ensuring safety and 
efficacy and marketing of the drugs
2
. This work will only be focusing on the drugs for 
humans, overlooking, this way, the production of drugs for animals and the medical 
devices. Henceforth, as the author refers to the pharmaceutical industry, only that 
specific sector is being referred to. 
Due to its huge size and intrinsic complexity, the pharmaceutical industry can be 
segmented in several ways. Focusing just in the human sector, one basis of 
segmentation would be the nature of the drug, i.e., a chemical or small molecule drug 
versus a biologic or large molecule drug (Singh, 2005). For the sake of this analysis the 
segmentation will be based on the product type. On Figure 1 it is possible to realize the 
type of segmentation adopted. Highlighted are the branches which are considered 













                                                   
2
 http://en.wikipedia.org/wiki/Pharmaceutical_industry [accessed on 08-04-2012] 
3
 MA stands for Marketing Authorization 
4
 OTC stands for Over-the-counter. An OTC drug is a medicine that can be sold directly to a consumer 
without a prescription from a healthcare professional. 
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i. The Industry Worldwide 
a) Mission 
Prolong, improve and save lives. One way or another, this declaration can be found in 
all the different pharmaceutical companies’ mission statements around the world, 
making it the ultimate business objective for the industry. Regard some examples: 
 
Pfizer (USA) – “…we at Pfizer are committed to applying science and our global 




GlaxoSmithKleine (UK) – “We have a challenging and inspiring mission to improve 





Novartis (Switzerland) – “We want to discover, develop and successfully 
market innovative products to prevent and cure diseases, to ease suffering and to 




Takeda (Japan) – “We strive towards better health for patients worldwide through 




In a few words, companies strive to achieve this common goal by whether treating and 
preventing diseases or by reducing their appearance and the problems associated with 
old age. This fact withstands the uniqueness of this industry, as the access to health care 
services and products are considered a personal right or a universal entitlement (Singh, 
2005).
 
                                                   
5
 http://www.pfizer.com/about/ [accessed on 08-04-2012] 
6
 http://www.gsk.com/mission-strategy/index.htm [accessed on 08-04-2012] 
7
 http://www.novartis.com/about-novartis/our-mission/index.shtml [accessed on 08-04-2012] 
8
 http://www.takeda.com/about-takeda/corporate-philosophy/article_61.html [accessed on 08-04-2012] 
 
CATÓLICA-LISBON School of Business & Economics 
Manuel Coimbra  4 
b) Industry Growth Rate 
The industry’s growth rate in the last decade has been remarkable, notwithstanding the 
downward trend of the growth over the previous periods. In 2010 the total world market 
was evaluated in US$856 billion
9
, while in 2003 it was capped at US$500 billion (see 
Exhibit 1). In 2010, the growth rate over the previous year was 4,1% (see Exhibit 1), 
being the major contributors for this progress the prevalent availability of generic drugs, 
the breakthroughs on therapy areas like oncology, diabetes, multiple sclerosis and HIV, 
which annual growth is expected to exceed 10 percent through 2014
10
, and the rise of 
the “pharmerging” markets. 
The “pharmerging” markets are a set of 17 countries
11
 where sales are forecast to grow 
by 13-16 percent over the next years, boosted by the greater government spending on 
healthcare, the expansion of the national health systems and the increasing domestic 
demand, and the specific agreements for the export of medicines for these developing 
countries. Within this group there is the special case of China, the third largest 
pharmaceutical market in the world, which is expected to grow at a pace of more than 
20 percent annually (see Exhibit 2). On the other hand, European countries and Canada 
will face a great slowdown, growing by 1-3 percent, and the US will remain as the 
largest market, with sales of US$320-330 billion, up 3-5 percent (IMAP, 2011). 
On the topic of the generic drugs, the many patent’s expirations in the following years 
will allow the industry to grow further. As in 2009 the market for these drugs was worth 
US$107.8 billion, by 2014 it is expected to reach US$129.3 billion, as a result to the 
rising cost pressure on healthcare and the improved accessibility to healthcare on the 
emerging markets (IMAP, 2011).  
As a result, the global pharmaceutical market is expected to expand to US$1.1 trillion 
by 2015, where the US represents 31% and the top 5 European countries 13%, values 
that in 2005 were 41% and 20% respectively, and the “pharmerging” markets 28%, as 
opposed to 12% in 2005 (see Exhibit 3). 
                                                   
9






xtoid=4b8c410b6c718210VgnVCM100000ed152ca2RCRD [accessed on 08-04-2012] 
11
Emerging markets targeted by pharmaceutical companies (Pharm(aceutical) + (e)merging). List of 
Pharmerging countries includes Argentina, Brazil, China, Egypt, India, Indonesia, Mexico, Pakistan, 
Poland, Romania, Russia, South Africa, Thailand, Turkey, Ukraine, Venezuela and Vietnam 
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c) Top companies 
In the pharmaceutical industry, loosely, there are two types of companies. The major 
players which are known for investing a lot in R&D in order to provide new and 
innovative drugs to the market (generally called the Big Pharma) and the smaller 
companies that manufacture products with expired patents or without brand, usually 
generics, or that are focused on specific therapeutic areas. While the first are companies 
located in advanced industrial societies, the latter are very significant in countries like 
India, China or Brazil (Busfield, 2003), three of the “pharmerging” markets, which year 
after year have been gaining market share at the expenses of US and Europe (IMAP, 
2011). 
The leading companies in this industry are large scale enterprises operating worldwide 
not only in terms of sales, but also regarding production, through subsidiaries and 
affiliates (Teixeira de Carvalho, 2007). From the Fortune Magazine Global 500 
Companies ranking it is possible to find eleven pharmaceutical giants (see Exhibit 4). 
All hosted in western countries, five are from the US, two are British and other two are 
Swiss, plus Germany and France with one each. Together, they total more than US$501 
billion in revenues and employ directly about 951 thousand people. 
In terms of sales, the top 10 companies represent around 44% of the total industry, a 
value superior to US$350 billion (see Exhibit 5). Regarding this topic it is important to 
notice the price-elasticity of the demand is almost zero, since each company, once a new 
drug is developed, approved and patented, owns the right to be the only one distributing 
and selling that drug. This exclusivity can bring perverse upward incentives on price 
levels, nevertheless, as one will see later, that price premium is essential for these 
companies to survive. 
Comparing with other industries, the 5 companies with more revenues from sales in 
2010 represented around 27% of the total industry sales (see Exhibit 5) which is a low 
concentration value when compared with the Aerospace (95%) or the Automotive 
(50%) (Ferreira et al., 2011).  In spite of the fact that it can be considered a concentrated 
industry, the possibility of companies to specialize in different specific segments (e.g. 
oncology, antidiabetics, etc.) results in a relative reduction of the weight of the biggest 
companies on the total turnover (Ferreira et al., 2011). 
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d) R&D 
Amongst the largest companies, the competitive advantage is based on product 
differentiation rather than on price leadership. The differentiated products are the result 
of enormous investments in R&D and marketing within the scientific and medical 
communities. Companies invest a lot in R&D and, thus, are extremely dependent on the 
success of their new products. They use trademarks and patents to protect new findings 
and maximize their potential profit, while current revenues are obtained from still 
patented products (IMAP, 2011). These are the funds that subsidize the expensive 
process for finding new drugs, turning this industry into the number one on percentage 
of total sales allocated to R&D (Bhattacharya et al., 2005). Just to have a grasp of what 
this value represents, in 2010, the percentage of sales that went to R&D industry-wide 
was 17% (PhRMA, 2011), around US$ 67.4 billion (Burrill & Co., 2011). This may 
seem a lot, however, studies show that for each dollar spent on new drugs, US$6.17 are 
saved in hospital spending (Lichtenberg, 2002). 
Regard some interesting facts: 
 It takes 10 to 15 years (DiMasi, 2001; Dickson and Gagnon, 2004; DiMasi, 
Hansen and Grabowsi, 2003) and US$1.3 billion (DiMasi and Grabowski, 2007) 
to develop a new drug (see Exhibit 6). 
 Only 1 out of every 10.000 discovered compounds actually becomes an 
approved drug for sale.
12
 




 Only 1 out of 3 approved drugs generate enough revenues to cover the 
developmental cost of previous failures.
12
 
Facing this numbers, the bottom-line is that if a company wants to survive in this 
industry, it must discover a blockbuster (billion-dollar drug) every few years
12
. One 
may understand now, how essential are the intellectual property rights conferred by 
patents. Without patent protection it would not be feasible to develop new drugs. 
                                                   
12
 http://www.medicinenet.com/script/main/art.asp?articlekey=18892 [accessed on 18th April 2012] 
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e) M&A 
The oligopolistic structure and subsequent consolidation of this industry have been 
reinforced over the past years by means of an eventful period of mergers and 
acquisitions among the companies in higher positions. Since the beginning of this 
millennium it is worth stressing the acquisition on Warner Lambert by Pfizer in 2000 
for US$90 billion, as well as the acquisition in 2004 of Aventis by Sanofi-Syathelabo in 
exchange for US$65 billion (see Exhibit 7). More recently, in 2009, the pharma sector 
saw 563 deals valued at US$161.2 billion, having been the largest one the acquisition of 
Wyeth by Pfizer for US$67.9 billion. 
In 2010, the acquisition spree seemed to slow down with 548 deals valued at US$51.6 
billion taking place. The major deal in this period was the acquisition of Ratiopharm by 
Teva Pharma for US$4.9 billion (see Exhibit 8). These mega deals justify the presence 
of the United States and Europe at the top in terms of transaction value, however, 
looking at numbers as the quantity of deals, China, a market that is expected to grow 20 
percent per annum through 2013 (Zacks Equity Research, 2012), appears as the leader 
in micro-size deals of less than US$20 million (see Exhibit 9). 
The acquisition of other companies operating upstream and downstream the supply 
chain is an alternative to the internal development. These million-dollar operations are 
seen as the quickest and neatest way to gain access to new capabilities (intellectual, like 
knowledge, or physical, like distribution channels) and to expand the product portfolio. 
They not only allow companies to penetrate in new markets and to incorporate new 
R&D skills, but they also increase firm’s investing ability in new product development 
processes. Moreover, they work as a way to avoid future decreases in income due to the 
expiration of patents on current successful drugs (Ferreira et al., 2011). 
This consolidation through M&A and licensing activity is bound to grow further in the 
future as companies urge to adapt to the changing conditions within the industry. Since 
developing a product from scratch involves a lot of funds, pharmaceutical companies 
opt to shop for mid to late-stage pipeline candidates. They can come as a result of 
complementary capabilities between firms. For instance, while a small company may 
have a new drug, but lacks on sales and marketing capabilities, a large company may 
have an unused capacity in a large sales force. It is a matter of capitalizing the synergies 
between the companies. 
 
CATÓLICA-LISBON School of Business & Economics 
Manuel Coimbra  8 
From a survey conducted by Business Insights, 91 percent of industry executives 
believe pharma-biotech mergers will increase in the next 10 years (IMAP, 2011). 
ii. The Industry in Portugal 
a) Industry Growth Rate 
The evolution of the Portuguese pharmaceutical industry has been similar to the global 
until recent years, the moment when the “pharmerging” countries started to disrupt. In 
terms of manufacturing of raw materials and pharmaceutical products, a flourishing 
period of growth started in 1996. From that year until 2008, a time frame of 12 years, 
the industry almost doubled its value, growing from 1.045 million € to 2.054 million €. 
In 2009, however, there was a negative growth when 1.975 million € were produced 
(see Exhibit 10), which represents around 0.31% of the value of the pharmaceutical 
market worldwide. 
b) Employment 
This is an industry which directly employs 10.244 people (2008). Indirectly, there is no 
actual data regarding Portugal, however, looking at the US, in 2008, there were 655.000 
direct jobs, while indirect and induced jobs
13
 reached a value of 2.440.000 (Archstone 
Consulting and Burns, 2010). This creates a Ripple Effect meaning that each job in the 
pharmaceutical industry supports almost 4 others. Those jobs are distributed amongst 
the 347 medicines wholesalers, 2693 pharmacies, 221 pharmacy extensions and 838 
drug stores (Infarmed, 2009), places that only sell OTCs, that Portugal had in 2009. 
c) Top Companies 
The top 20 pharmaceutical companies in Portugal, in a universe of 137
14
, are 
responsible for 60% of the market mainly because of the presence of large multinational 
companies like Merck, Pfizer or AstraZeneca (Teixeira de Carvalho, 2007), which are 
also the leaders on a global scale. The biggest Portuguese company is Bial, which is 
currently ranked 5
th
 (see Exhibit 11) and was the company that first released to the 
                                                   
13 Indirect jobs are jobs that produce goods or services used to support biopharmaceutical companies. 
Induced jobs are jobs supported by the spending of direct and indirect employees of the 
biopharmaceutical sector. 
14
 APIFARMA’s membership (manufacturers or importers) 
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global market a drug made in Portugal. It closed 2011 with a turnover worth 140 million 
€ from which 85.6 million € were from the Portuguese market
15
.  
The second Portuguese company that most sells in Portugal is Generis, with 46.9 
million €, followed by Medinfar and Tecnifar, with 42.5 million € and 26.6 million €, 
respectively. Fifth comes Lusomedicamenta and in the sixth, eighth and tenth places 
there are Pentafarma, Farmoz and Tecnimede, in that order. As they belong to the same 
group, if totaled together, the group would come third on the top with sales of 42.9 
million € (see Exhibit 12). 
d) Industry Total Value 
Regarding total sales at ex-factory prices, the total value in 2011 was 3.716 million €, 
having grown roughly 1.000 million € since 2005 (see Exhibit 13). Easily, one realizes 
that imports play a crucial role in this sector, being their value in 2009 capped at 2.194 
million €, while exports were five times smaller, representing 447 million € (see 
Exhibit 14). In spite of this value, a study from Universidade do Minho shows that 
Portuguese exports are growing at twice the pace of the world’s average. As in Portugal 
the growth of this segment was 13.8%, globally, this value did not exceed the 7.4%. The 




e) Ambulatory Market and Hospital Market 
Looking now at retail prices, it is possible to disassemble the total market in two 
categories, the Ambulatory Market and the Hospital Market. This is one step more 
towards the desired segmentation. 
In 2009 the total market value was 4.728 million € divided ¾ - ¼ between ambulatory 
and hospital markets, respectively. They both have been expanding throughout the last 
years, however, as the ambulatory faced a growth rate of -0.9% in 2008, the hospital 
market experienced, in this same year, an expansion of 7%. In 2009, the hospital market 
                                                   
15
 Neves, R. (2012) Nove Portuguesas no “top 50” de vendas nacional. Jornal de Negócios Online. 
Available in  http://www.jornaldenegocios.pt/home.php?template=SHOWNEWS_V2&id=553185 
[accessed on 14-05-2012] 
16
 Peixoto, M. (2012) Exportações do sector da Saúde crescem o dobro da média mundial. Diário 
Económico Online.  Available in http://economico.sapo.pt/noticias/exportacoes-do-sector-da-saude-
crescem-o-dobro-da-media-mundial_144225.html [accessed on 14-05-2012] 
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was valuing 1.145 million €, around 25% of the total market, a clear growth since 2005 
when this percentage was 19.2% (see Exhibit 15). 
f) Hospital Market – MA and SUA 
Considering exclusively to the hospital market it is possible to breakdown the total 
value in two categories, as illustrated in Figure 1 – drugs with an active Marketing 
Authorization and drugs which need a Special Use Authorization, commonly called, 
unlicensed drugs. These certifications are both under the umbrella of Infarmed17. 
For this segmentation the data available refers only to some hospitals from the Health 
National Service, therefore one must analyze it in a critical way, bearing in mind that in 




In the year of 2011 the market for drugs subjected to a SUA was valuing around 5.5 
million €, which represented 0.5% of the hospital market of 57 institutions which 
values, approximately, 1.000 million €. Looking at the numbers from 2009 in order to 
compare them with the data available regarding all the universe of Portuguese hospitals 
(4.728 million €, recall Exhibit 15), one can see that the SUA market represented 
around 1% of the hospital market of 50 hospitals, roughly 6.5 million € in a total of 670 
million € (see Exhibit 16). This result is nearly 15% of the “true” value considering all 
the hospitals. As it may not be right to assume that this function is linear, predicting a 
value does not come as an easy task. A value somewhere between 20 and 30 million 







                                                   
17
 INFARMED,I.P. spells its company name in uppercase letters. The author has followed standard 
editorial style for company names that are not acronyms and capitalized only the first letter 
18
 http://www.pordata.pt/Municipios/Hospitais+total+e+por+natureza+institucional-247 [accessed on 27-
05-2012] 
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INFARMED, I.P., the National Medicines and Health Products Authority
19
 is the 
executive agency of the Ministry of Health that is responsible for the evaluation, 
authorization, regulation and control of human medicines and health related products as 
medical devices and cosmetics. It is a public corporate body, under the state’s indirect 




The main goal of the organization is to ensure quality, safety and efficacy of medicines 
and the quality, safety and performance of health products in order to avoid the risks of 




Infarmed undertakes an important role in the fields of policy making and execution, 
regulation, evaluation, authorization and post-marketing vigilance and supervision. It 
controls the research, production, distribution and marketing, consumption and use of 
medicines, medical devices and personal hygiene products in Portugal. It is also 
Infarmed’s responsibility to promote to health professionals and to the general public 
the access to information necessary for rational use of medicines, medical devices and 
personal hygiene products. Moreover, they support the research in the fields of 
pharmaceutical science and technology, biotechnology, pharmacology, 
pharmacoeconomics and pharmacoepidemology. 
 
                                                   
19
 In Portuguese, INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde I.P. 
20
 http://www.infarmed.pt/portal/page/portal/SOBRE_O_INFARMED/APRESENTACAO [accessed on 
21-05-2012] 
21
 http://www.infarmed.pt/portal/page/portal/INFARMED/ENGLISH/ABOUT_INFARMED [accessed 
on 21-05-2012] 
 
INFARMED, I.P., the National Medicines and Health Products Authority19 is the executive 
agency of the Ministry of Health that is responsible for the evaluation, authorization, 
regulation and control of human medicines and health related products as medical devices 
and cosmetics. It is a public corporate body, under the state’s indirect administration, 
endowed with administrative and financial autonomy and its own assets20. 
The main goal of the organization is to ensure quality, safety and efficacy of medicines and 
the quality, safety and performance of health products in order to avoid the risks of their use, 
while ensuring adequate standards of public health and consumer’s protection21. 
The Mi sio : 
“To regulate and supervise the medicinal and health products sectors, in accordance with 
the highest standards of public health protection, and ensure access to high quality, effective 
and safe medicines, medical devices and cosmetic and personal hygiene products to health 





“To be a model of excellence in quality public service provision and a reference agency the 
European Union, while valuing its employees.” 
 
 
Infarmed undertakes an important role in the fields of policy making and execution, 
regulation, evaluation, authorization and post-marketing vigilance and supervision. It 
controls the research, production, distribution and marketing, consumption and use 
of medicines, medical devices and personal hygiene products in Portugal. It is also 
Infarmed’s responsibility to promote to health professionals and to the general public 
the access to information necessary for rational use of medicines, medical devices 
and personal hygiene products. Moreover, they support the research in the fields of 
pharmaceutical science and technology, biotechnology, pharmacology, 
pharmacoeconomics and pharmacoepidemology 
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1.3 Prologue 
It took seven minutes for the ambulance to arrive at Hospital de Santa Maria in Lisbon. 
Seven long minutes inflated by the rush hour that haunts the city every time the clocks 
reach the 6 o’clock.  
While the ambulance was drifting through the Avenida dos Estados Unidos da América 
the paramedics weren’t sure about what to do. She was 23. Her blood pressure was 
skyrocketing. The prognosis wasn’t good for both of them. 
Two weeks before she had noticed that her blood pressure was increasing, a sign she 
believed to be normal as the pregnancy was progressing, but only that afternoon she 
started to feel some dizziness and her legs have never been so swollen.  
The presence of advanced chronic kidney disease and pregnancy is an uncommon 
occurrence with an incidence between 0.002 and 0.01%.  She still had two weeks before 
delivering, however, doing so on that rainy day seemed to be the only option. 
Once they arrived at the hospital she required treatment with Labetalol due to the 
increased BP and the labour was induced on the grounds of intrauterine growth 
restriction. The baby was born weighting 1.640g (3-10percentile) and in respiratory 
distress.  
 
The infant was discharged at 23 days of age and three months later the mother was 
asymptomatic.  
This case has been adapted from a true story reported on Revista Nefrologia, April 2010. All medical 
information has been preserved. 
Source: Merino JL, Espejo B, Ferreiro P, Bueno B, Paraíso V. Pregnancy and advanced chronic kidney 
disease. Nefrologia. 2010; 30(3): 376-8 
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1.4 The Business Opportunity 
Labetalol is one of the drugs for which there is not an active Marketing Authorization in 
Portugal. The reasons can vary from economical, when a company is not interested in 
export it due to its low business value, to logistical, when a firm has no resources to 
export it by itself, or even opportunistic, when a new drug was approved in all the 
efficacy and security clinical trials and the MA is already being requested in other 
country but was not granted yet. 
In order for this drug to arrive at a Portuguese hospital, a lot of procedures and 
paperwork must be undertaken leading to a delay in one of the most important success 
factors in a hospital, response time. Multiplying this action for each drug the hospital 
may need the business opportunity becomes clear: To act as an auxiliary between 
hospitals and pharmaceutical companies. 
This was the rationale behind the creation of Unipharma: distribute drugs for treating 
rare or uncommon conditions in Portugal. 
Pedro Azevedo, 46 years old, started to work in the pharmaceutical industry as soon as 
he was discharged from the military in 1987. He was a 21-year-old young man with a 
lot of dreams in his green camouflaged backpack and a great will to start his life. Still 
galvanized by Madjer’s back-heel that May 27
th
 evening, he began to work as a medical 
sales representative for a French multinational company. After 13 years employed in the 
industry, having worked for companies like Bayer or Baxter, and an Executive Training 
Program from Católica-Lisbon in his résumé, Pedro was invited in 2002 to become part 
of the creation of a new Portuguese company in the area of biotechnology. He has been 
the senior business manager responsible for sales and marketing of a biotech company 
for 10 years now. 
In 2006, after innumerous discussions with his longtime friend Miguel Pinto, an expert 
in tax and financial accounting, about this flaw in the national market, Pedro finally 
convinced him to join him in this adventure. This was the beginning of Unipharma. 
Pedro and Miguel were committed to defy the status quo in order to improve the 
efficiency and efficacy of Portuguese hospitals. 
Having both kept his job, the two years of market research were extremely demanding 
and exhausting. There was a lot of work to be done, people with whom to talk and 
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hospitals to be informed about the new service. It would not be worth to offer drugs that 
hospitals would not be interested in buying. All this information needed to be collected 
while respecting a relatively low budget. 
The company was formed as a private limited liability company with a capital of 5.000 
€, the minimum required at the time, split equally between the two managers. Without 
recurring to any financial institution or external investor both entrepreneurs used their 
own debit and credit cards to buy their equity in the company, to pay all the initial 
expenses and to fund their working capital. It was a case of bootstrapping. 
In 2008, for Pedro and Miguel delight, the company finally started operating under the 
name of Truepharma – Import e Export, Lda.
22
 containing in its portfolio 5 products for 
which there were already various orders from some of the most important Portuguese 
hospitals like Hospital de Santa Maria, Hospital de S. José, Hospital de S. João, Centro 
Hospitalar de Coimbra or Centro Hospitalar do Barlavento Algarvio . The drugs in 
question were the Isoprenaline, the Triamcinolone, the Fludrocortisone, the 
Phenoxbenzamine and the Ciclozerine. 
At the beginning Truepharma had two key partners which were essential for the success 
of the company. On the supplier side, Truepharma associated with a British 
multinational company named Idis, which was already running this kind of business in 
other countries. Despite having different interests in the partnership, this alliance paid 
off for both of them. Truepharma was receiving the drugs from Idis which simplified 
the procurement process, and the latter was able to enter in the Portuguese market with 
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 Henceforth called only Truepharma for simplifying 
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The second important partner is Dilofar, a Portuguese specialist in logistics and 
distribution in the pharmaceutical industry. The commercialization of medicinal 
products for human use is subject to legal requirements and calls for an authorization 
from Infarmed. Another important aspect of this partnership was the fact that 
Truepharma still did not have that license to be a wholesaler of medicinal products for 
human use, unlike Dilofar, therefore, this outsourcing opportunity was irresistible. 
Truepharma benefited from Dilofar services, which in this industry must comply with 
an endless list of regulations, without having had to engage in huge initial investments. 
Still today, Dilofar is the company that stores and ships the drugs among all the 





Around the world, patients with unmet medical needs are frequently driven to seek access 
to medicines outside the clinical trial and commercial setting. Idis is the leading expert in 
developing, implementing and managing global Managed Access Programs by which 
pharmaceutical and biotechnology companies and healthcare providers can respond to 
the needs of these patients. 
Idis has 25 years experience of partnering with pharmaceutical and biotechnology 
companies to create regulatory-compliant, ethical access to medicines for healthcare 
professionals and their patients with unmet medical needs. 
Since 1987, Idis has developed and managed access to thousands of medicines from 
virtually every therapeutic category, impacting the lives of hundreds of thousands of 
patients in countries around the world. 
Excerpt taken from http://www.idispharma.com/about-us 
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During two years, 2008 and 2009, Truepharma operated in this manner, facing 
turnovers of 450.000 € and 600.000 €, respectively. This is a proof that this system was, 
indeed, creating value to the hospitals. 
The following year, 2010, was prone to changes. Idis decided it was time to enter by 
itself in the Portuguese market and quitted the partnership. Instead of refraining, Pedro 
and Miguel went for the fight and created Unipharma. The next few months were of 
extreme hard work. Since Idis was the exclusive supplier, they had to search for new 
companies which could provide them reliable drugs. 
The new company was created as a S.A. with a capital of 50.000 € from which the only 
shareholder is Truepharma with an interest of 100%. Once again, the duo opted to avoid 
any external funding. 
This was a significant upgrade to the company since from that moment on it was not 
just about the paperwork to obtain the SUA, but also about the procurement, inward and 
 
Dilofar - Distribuição, Transportes e Logística, Lda, is a logistics company that operates 
exclusively in the pharmaceutical industry. It capitalizes on all the “know-how” and 
experience accumulated over more than 70 years in the market for distribution of 
medicinal products. 
Certified by ISO 9001:2008, Dilofar ensures coverage of mainland Portugal and the 
Autonomous Island Regions. It pretends to position itself as a reference Logistics 
Operator in the national market for distribution of pharmaceuticals that can provide a 
fast, reliable and high quality service. 
From the logistics, complemented with the financial operations (billing and collection) 
and the services of labeling, assembly, pharmacovigilance and regulatory affairs, Dilofar 
has conditions to ensure a complete high quality service, making it the number one in the 
Portuguese market. 
Excerpt taken, adapted and translated from http://www.dilofar.pt 
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outward. Unipharma’s activity consists on searching, obtaining and supplying 
recognized quality pharmaceutical products which are subject to a SUA in Portugal. The 
products should be of the highest quality, economically feasible and with recognized 
origin. The ultimate goal is to launch, promote and firmly implement these innovative 
drugs in the Portuguese hospital market. Additionally, another aspect on which 
Unipharma started working was the promotion of Portuguese manufactured drugs 
overseas. At the end of the year the portfolio was consisting of 14 new drugs. 
“Every cloud has a silver lining. If this would have happened one or two years later it 
would be practically impossible for us to overcome the situation because the market 
would be to “stuck” on those specific products.” 
Pedro Azevedo, 30th May 2012 
Dilofar remained as a partner, warehousing and shipping the products. 
According to Unipharma’s website, these are the mission statement and vision of the 
company: 
 Mission 
We are committed to deliver unconditional support to Portuguese hospitals on 
searching, obtaining and supplying pharmaceutical products of undeniable quality, 
feasible economically and always from a recognized source (EU, USA, Canada and 
Japan), subject to SUA. 
We work in order to support other worldwide companies searching and obtaining 
pharmaceutical products of Portuguese origin with recognized quality and duly licensed 
by the Portuguese authorities. 
It is also our concern to support hospitals obtaining pharmaceutical products for rare 
diseases. 
 Vision 
We value, above all, our ability to serve Portuguese hospitals in developing the 
bureaucratic process like filling in the required forms and sending them by electronic or 
post mail. We want to offer competitive prices with no further costs on the provided 
service and we always present the costs on the European official currency. 
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We are proactive in searching pharmaceutical products for the treatment of rare diseases 
no matter its prevalence. 
We are proactive in licensing each product in Portugal, whenever allowed by its 
manufacturers. 
We are proactive in remarking the quality of Portuguese pharmaceutical products in the 
treatment of patients all over the world whenever they are necessary. 
 
The criteria for a drug’s approval by the Infarmed for a special use are very tight. First 
of all, only drugs with a MA from the European Union countries, USA, Japan or 
Canada are eligible. Then, the MA from the country of origin and the Summary of 
Product Characteristics must be delivered to the Infarmed translated and approved by 
the producer. These are the elements that should be stated: 
a) Identification of the health facility where the drug will be used; 
b) Identification of the drug, including its qualitative and quantitative composition 
of active substance, pharmaceutical form and presentation; 
c) Identification of the MA holder in the foreign country, country of registration, 
manufacturer, country of manufacture, liberating batch, country of releasing, 
distributor in the country of origin, distributor in Portugal and customs; 
d) Indication of the price per unit and an estimate of the total expenditure; 
e) Copy of the MA from the country of origin, or preferably, the last renewal 
accompanied, when applicable, with a proof that the MA still remains valid or, 
alternatively, the WHO export model identifying the MA holder; 
f) A copy of the updated Summary of Product Characteristics; 
g) In the case that the drug is not acquired under the MA in a UE Member State or 
in a country with which there is not a mutual recognition agreement, 
presentation of a written document of compliance with good manufacturing 
practices. 
Moreover, Infarmed requires that a form is filled and delivered by a clinical director. As 
neither Pedro nor Miguel were pharmacists, Dra. Joana Silva joined the Unipharma 
team in April 2010. 
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The applicants must, normally, submit every year during September, a single 
application of SUA for each drug with well-recognized clinical benefit. An approved 
SUA is valid for one year, starting the following January. The applicant must also 
ensure that the product is accompanied by a document in Portuguese, stating the 
conditions of storage, keeping, handling, manipulation, compatibilities and 
incompatibilities, stability, post-reconstruction and post-dilution expiration and 
administration, so that such information is accessible to users that may need. 
In spite of all the changes, the company continued prospering, presenting in the first ten 
months of 2010 a turnover of 700.000 €. 
In October 2010 Unipharma was finally granted Infarmed’s license to be a wholesaler 
of medicinal products for human use, nevertheless, that activity was kept outsourced, 
once again, trough Dilofar. 
As the portfolio was being enlarged, also the money coming in was increasing. Another 
collaborator was hired to personally go from hospital on hospital offering the service.  
Due to some new products’ transport specifications which required refrigerated 
transport, the contract with Dilofar was renegotiated, passing from 3.9% for 4.9% of the 
invoicing. Yet, the profit kept growing as the turnover from the last 2 months in 2010 
together with 2011 peaked the 1.8 million €. 
Today, Unipharma holds 47 products in its portfolio. The 16 most sold are showed in 
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Table 1. Unipharma’s top medicines in terms of sales 
 Description Sales 2011 
1 Cycloserine 210.000,00 € 
2 Isoprenaline 0,2mg/ml 10 pills box 185.000,00 € 
3 Ethionamide 147.500,00 € 
4 PAS (4-Aminosalicylic acid) 147.000,00 € 
5 Prednisolone 25mg 89.000,00 € 
6 Labetalol 100mg/20ml Injectable Solution 20ml Flask IV 80.000,00 € 
7 Capreomycin 80.000,00 € 
8 Triamcinolone 40mg/ml Injectable Solution 1ml Flask 67.000,00 € 
9 Foscarnet 24mg/ml Injectable Solution 250ml Flask 52.500,00 € 
10 Mercaptopurine 50mg 46.000,00 € 
11 Etoposide 100mg Capsules 39.800,00 € 
12 Fludrocortisone 0.1mg pills 35.400,00 € 
13 Etoposide 50mg Capsules 29.000,00 € 
14 Scleremo 0,8% + 72% 5ml 5 ampoules box 25.000,00 € 
15 Sulfadiazine 500mg 100 pills box 21.000,00 € 
16 Isoprenaline 0,2mg/ml 6 pills box 12.000,00 € 
Source: Unipharma internal company records 
In terms of market share, as of 2011, Unipharma comes second with 30%, behind Idis 
with 50% that despite having higher prices can offer a broader range of products. The 
remaining market is divided among smaller companies like Clinigen, Overpharma, 
Genopharma or Pharmispharma which cannot be competitive due to the reduced 
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1.5 The Changed Paradigm 
Before Truepharma/Unipharma
23
, hospitals had to contact each producer independently, 
followed by all the bureaucratic process required by Infarmed for obtaining the 
respective SUA. Only after this period, if the SUA was granted, the hospitals could 
contact the producer again for the discussion of prices. Prepayment was always required 
and then, finally, the drugs would be shipped to Portugal. It was a process that could last 
up to two months. Today, with this company, the process can be concluded in a matter 
of days. The benefits for the hospitals are obvious, as Unipharma takes the 
responsibility for all the important steps of the import process: 
 the Infarmed’s requested forms; 
 the procurement; 
 the acquisition; 
 the warehousing; 
 the distribution. 
On the top of that, the unitary price of each drug the hospital pays is lower than when 
bought directly to the producer, due to Unipharma’s increased bargaining power derived 
from the greater quantities purchased. In terms of delivering time, it was reduced for 24 
to 48 hours. The company preferably works in a prepayment scheme, however, in 
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 Henceforth called Unipharma in order to simplify, but always referring to the moment the company 
started 
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Meanwhile, on the other side of the fence… An interview with a 
Director of Pharmacy 
Interviewing the Director of Pharmacy of one hospital which buys from Unipharma 
was an interesting exercise to see things from the opposite point of view. 
A Director of Pharmacy is the responsible for the efficient operation of the hospital 
pharmacy. Among other tasks, he is the person responsible for the planning and 
coordination of all the activities regarding the drug’s procurement process, a practice 
that, for SUAs in particular, was, in his words, “very exhausting and time consuming 
as we needed to contact each producer directly”. 
After a quick glance on how the process was before and on some important political 
issues he admitted that for him, the first advantage Unipharma provides is the 
reduction of the bureaucratic burden for the hospitals which contributes for the 
acceleration of the process. Nevertheless, this was not considered the most important 
since it only implies a reduction in the workload. The real advantage is the possibility 
to manage the acquisition of the products not by their unitary price but by the cost of 
the package provided. This bundle includes, usually, the product and all the implied 
procedures to obtain it, the shipping, the customs clearance when needed and the 
delivering. “Knowing this value putting the existing companies in a war of prices is 
really easy”, still, there are other services that can make the difference. And the 
pharmacist proceeded with an example: “Imagine that I order 600 ampoules of a 
given drug. I am getting to the end of their expiration date and I still have 100. I call 
the company from where I bought them (in this case, Unipharma) and they manage to 
allocate them to other hospital that is currently in need. With this action I saved costs, 
despite having paid a premium for the ampoules. If I had bought from other company 
at a lower unitary price but that wouldn’t allow me to make these gymnastics, I would 
have lost more money.” 
Concluding, the strategic advantage of Unipharma is empowered by other services 
they provide so that the cost for hospitals can become lower. The important thing is 
that “the client perceives additional services as being part of the final cost” whether 
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1.6 Conclusions 
Just like the situation of the young pregnant woman described above, there might be in 
Portugal hundreds of different cases which drugs sold by Unipharma come in handy or 
otherwise the patient would not get the best medical treatment possible. For the 
unfortunate people that require these products, the value added provided by Unipharma 
might be close to a maximum, if that conception even exists. 
Although 2012 is exceeding the initial expectations, the prospect that the national 
market is decreasing together with the fact that foreign companies are becoming more 
competitive in prices due to their countries’ lower tax rates, cause serious threats to 
Unipharma. 
The future is already being planned and according to Pedro’s words the next years seem 
promising: 
“We want to become a global reference.” 
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Figure 2. Total Pharmaceutical Market Sales, 2003 – 2010 
Source: IMS Health Market Prognosis, March 2011 
 
 
















Exhibit 2 – List of Pharmerging Countries 
Table 2. List of Pharmerging Countries 
Tiers Countries 
































Source: IMAP’s Pharmaceuticals & Biotech Industry Global Report (2011), IMAP, Turkey 
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Figure 3. Spending in the Pharmaceutical Industry by geography 
Source: IMS Market Prognosis, April 2011 
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Exhibit 4 – The largest companies in the Pharmaceutical Industry 
Table 3. The largest companies in the Pharmaceutical Industry 








1 Pfizer USA 103 67.809 8.257 110.600 
2 Johnson & Johnson USA 123 61.587 13.334 114.000 
3 Novartis Switzerland 164 51.561 9.794 51.561 
4 Roche Group Switzerland 174 47.171 8.314 80.653 
5 Bayer Germany 178 46.473 1.723 111.400 
6 Merck USA 180 45.987 861 94.000 
7 Sanofi-Aventis France 187 45.056 7.241 101.575 
8 GlaxoSmithKline UK 194 43.857 2.524 96.461 
9 Abbot Laboratories USA 255 35.167 4.626 91.440 
10 AstraZeneca UK 281 33.269 8.053 61.100 
11 Eli Lilly USA 423 23.078 5.070 38.350 
 
Source: Fortune Magazine, The Global 500 Companies, 2011 
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Industry Sales 2010 
Pfizer Novartis Merck & Co. Sanofi-Aventis 
Astrazeneca GlaxoSmithKline Roche Johnson&Johnson 
Abbot Lilly Others 


















Figure 4. Top 10 Global Corporation in terms of sales 
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Figure 5. R&D phases of a new drug 
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Exhibit 7 – Major acquisitions in the Pharmaceutical Industry between 2000 and 2009 
Table 4. Major acquisitions in the Pharmaceutical Industry between 2000 and 2009 
Year Buyer Target Transaction value 
(in US$ billions) 
2000 Pfizer Warner Lambert 90 
2001 Bristol-Myers Squibb DuPont 
Pharmaceuticals 
7.8 
2001 J&J Alze 10.5 
2001 Angea Immunex 14.8 
2002 Pfizer Pharmacia 60 
2003 General Electric Amersham 9.5 
2004 Sanofi-Syathelabo Aventis 65 
2006 Merck KgaA Serono 13.3 
2006 Bayer Schering AG 21.5 
2007 Schering-Plough Organon BioSciences 14.5 
2007 AstraZeneca MedImmune 15.6 
2008 Tabeda Millenium 8.8 
2008 Novartis Alcan 11 
2009 Merck & Co. Schering-Plough 41 
2009 Roche Genetech 46.8 
2009 Pfizer Wyeth 67.9 
 
Source: Adapted from ITRI (2009), Invest in Taiwan, Industrial Technological Research 
Institute of Taiwan 
 
Exhibit 8 – M&A Activity in 2009 and 2010 
Table 5. M&A Activity in 2009 and 2010 
Particulars 2009 2010 
Total number of deals 563 548 
Deals with available transaction 
value 
314 309 
Total transaction value US$161.2 billion US$51.6 billion 
Largest Deal Acquisition of Wyeth by 
Pfizer for US$67.9 billion 
Acquisition of 
Ratiopharm by Teva 
Pharma for US$4.9 
billion 




Source: Thomson M&A Database, IMAP’s Pharmaceuticals & Biotech Industry Global Report 
(2011), IMAP, Turkey 
 
Exhibit 9 – Transaction values and Number of deals in 2010 
Table 6. Transaction values and Number of deals in 2010 
Top Five Countries No. of transactions Value (US$ billion) 
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United States 114 25.6 
Germany 18 5.4 
India 48 4.9 
China 105 3.4 
Brazil 13 1.9 
 
 U.S. Europe Japan China Latin America RoW TOTAL 
Undisclosed 
deals 
47 79 16 26 7 64 239 
Up to US$20 
Million 




















8 6 0 1 1 5 21 
TOTAL 114 134 27 105 19 149 548 
Source: Thomson M&A Database, IMAP’s Pharmaceuticals & Biotech Industry Global Report 
(2011), IMAP, Turkey 
 
Exhibit 10 – Manufacturing of Raw Materials and Pharmaceutical Products 





2000 1.493 13,8% 
2001 1.450 0,8% 
2002 1.469 1,3% 
2003 1.560 6,2% 
2004 1.590 1,9% 
2005 1.745 9,7% 
2006 1.829 4,8% 
2007 2.003 9,5% 
2008 2.054 2,5% 
2009 1.975 -3,8% 
 
Source: EFPIA; Apifarma 
Exhibit 11 – Top 10 Portuguese Pharmaceutical Companies 
Table 8. Top 10 Portuguese Pharmaceutical Companies 
 Company 
1 Merck Sharp Dohme 
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2 Pfizer 
3 AstraZeneca 
4 Novartis Farma 
5 Bial 
6 Servier 
7 Bayer Portugal 
8 Sanofi-Aventis 
9 GlaxoSmithKleine 
10 Lilly Portugal 
 
Source: IMS (Var M1 vs. M2 €) March, 2012 
 
Exhibit 12 – Top 10 “MADE IN” Portugal 
Table 9. Top 10 “MADE IN” Portugal 
 Company Sales (million €) 
1 Bial 85,6 
2 Generis 46,9 
3 Medinfar 42,5 
4 Tecnifar 26,6 
5 Lusomedicamenta 17,3 
6 Pentafarma 16,6 
7 Atral-Cipan 16,5 
8 Farmoz 16,1 
9 Tetrafarma 14,8 
10 Tecnimede 10,2 
 
Source: IMS Health 
This ranking elaborated by “Jornal de Negócios” uses data from IMS Heath and it only includes 
pharmaceutical companies controlled by Portuguese capitals, taking into account the sales from 
April 2011 to March 2012.24 
 
                                                   
24
 Neves, R. (2012) Nove Portuguesas no “top 50” de vendas nacional. Jornal de Negócios Online. 
Available in  http://www.jornaldenegocios.pt/home.php?template=SHOWNEWS_V2&id=553185 
[accessed on 14-05-2012] 
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Exhibit 13 – Portuguese Pharmaceutical Market Value (At ex-factory prices) 
Figure 6. Portuguese Pharmaceutical Market Value 
Source: EFPIA member associations (official figures)  
The figures above are for pharmaceutical sales, at ex-factory prices, through all distribution 
channels (pharmacies, hospitals, dispensing doctors, supermarkets, etc.), whether dispensed on 
prescription or at the patient’s request. Samples and sales of veterinary medicines are excluded. 
 
Exhibit 14 – Portuguese Imports and Exports of Raw Materials and Pharmaceutical 
Products 
 
Figure 7. Portuguese Imports and Exports of Raw Materials and Pharmaceutical Products 










2005 2006 2007 2008 2009 2010 2011 
In million € 





308 297 346 396 410 447 
-1.289 
-1.349 
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Exhibit 15 – Total Market in Value for Portugal 

















 4.164 4,7 4.359 3,4 4.508 3,9 4.683 0,9 4.728 
Ambulatory Market
(2)
 3.364 2,8 3.457 3,5 3.577 1,0 3.614 -0,9 3.583 
Prescription Medicines 3.112 3,3 3.213 3,9 3.338 1,4 3.384 1,0 3.350 
Non Prescription Medicines 252 -3,7 243 -1,6 239 -4,2 229 1,8 233 
Hospital Market
(3)
 800 12,7 902 3,1 930 15,0 1.070 7,0 1.145 
Units: Million Euros 
(1) Total Market = Ambulatory Market + Hospital Market 
(2) Ambulatory Market = Prescription + Non Prescription 
(3) Hospital Market of National Health Service 
Source: Apifarma, The Pharmaceutical Industry in Figures (2010), Portugal 
Exhibit 16 – Value of SUAs 
Table 11. Value of SUAs 
 Total Hospital Market 
(€) 
% relative to 
SUAs 
Value (€) # Hospitals 
2007 707.798.931 1,30% 8.899.095 64 
2008 573.227.979 1,50% 8.681.529 50 
2009 670.027.626 1% 6.491.863 50 
2010 993.787.331 0,80% 7.484.470 60 
2011 1.012.518.276 0,50% 5.494.492 57 
Source: 
http://www.infarmed.pt/portal/page/portal/INFARMED/MONITORIZACAO_DO_MERCADO/OBSERVATORIO/ANALISE_MENSAL_MERCADO/ANA
LISE_MERCADO_MEDICAMENTOS_CHNM [accessed 29-05-2012] 
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2. TEACHING NOTES 
2.1 Introduction 
The case-study “Unipharma, S.A.: Creating value delivering pharmaceutical drugs” was 
prepared so that it can be used as class discussion material. It is not the author’s 
intention to make use of it as an endorsement, a source of primary data or an illustration 
of effective or ineffective practices. 
The first chapter of this case consists of two parts. It starts with an analysis of the 
pharmaceutical industry, focusing on the specific segment where Unipharma operates, 
and then passes to the description of the company itself. All the relevant data is 
provided throughout both parts of the case therefore any additional information should 
not be necessary. 
2.2 Synopsis 
The pathway of Pedro Azevedo has always been related to the pharmaceutical industry.  
Having started as a medical sales representative without any prior experience, Pedro 
made his way to the top due to his hard-work, perseverance and resilience. Currently, he 
occupies the position of senior business manager in a successful Portuguese 
biotechnology company. Regardless of his busy professional life, Pedro was feeling he 
could do something more for the industry that took him when he was just a 21-year-old 
lad coming from the military service. As a result, in 2008, driven by his pro-activeness 
and entrepreneurial spirit, he started his own company together with a longtime friend. 
The objective was to illuminate a grey area in the Portuguese market regarding the 
unlicensed drugs for hospital use, a current practice in countries like France, England or 
Germany, but totally neglected in the smaller European countries. 
The company was a success and is consistently growing year after year. Its main 
competitor is a British multinational company that was firstly a partner and then turned 
to the other side. Together, they hold a market share of some 80%, being the other 20% 
held by smaller companies that have appeared in the market commercializing just 2 or 3 
products in specific therapeutic areas. 
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The future is being planned with a great focus on internationalization. Spain, Brazil and 
the more recent UE members are the most attractive targets. 
2.3 Suggested assignment questions 
1. From what you have learned during the reading of the case, how would you 
characterize Unipharma? In which industry does it operate? 
2. Unipharma only sells products conceived for rare or uncommon conditions. 
How would you justify the attractiveness of a market with such low demand? Is 
the market still attractive? 
3. What should be, in your opinion, the value proposition of Unipharma? 
4. In your opinion, what type of innovation does Unipharma stand for? 
Incremental or Disruptive? 
5. Considering that the SUA market in Portugal is not growing any further what do 
you suggest for the future? 
2.4 Teaching Objectives & Use of the Case 
The main teaching objectives of this case deal with strategy, entrepreneurship and 
innovation concepts. The students should be able to apply the correct theoretical 
frameworks in the appropriate situations so that a better analysis is accomplished. 
This case was conceptualized to be used in an undergraduate strategy course since it 
allows students to use and recall most of the theoretical topics learned during over the 
course of the semester in an innovative market, different from what is common on these 
courses. 
2.5 Analysis and Discussion 
The guiding lines to explore this case are based on the questions above proposed. The 
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1. From what you have learned during the reading of the case, how would 
you characterize Unipharma? In which industry does it operate? 
(This introductory question should serve as an ice-breaker. The instructor’s role should 
be provocative in order to stimulate discussion and controversy. 15 minutes should be 
enough to cover all the points.) 
By no means should ever be said that Unipharma is a pharmaceutical company. The 
company does not produce any medicinal product; it only provides a service related to 
the industry. The company operates in the pharmaceutical industry. It made use of all 
the regulations and bureaucracy regarding drugs subject to SUA and created a market 
where before there was nothing. 
Another interesting detail is that Unipharma is not a transport and logistics company 
whatsoever. Despite dealing with all the processes involving this industry, all these 
tasks are outsourced. 
Through the analysis of the marketing-mix one can easily understand the business: 
 Product / Service – Deliver medicines that need a SUA in the Portuguese 
Market, taking care of all the procedures between producers and hospitals 
 Placement / Channels of distribution – Outsourced to a company specialized in 
logistics in the pharmaceutical industry 
 Promotion – Advertising medicines that need a medical prescription is not legal 
in Portugal. Unipharma has one collaborator that goes, personally, to all the 
hospitals offering the service and inquiry about potential new additions. 
 Price – Try to be competitive enough that the final unitary price, all services 
included, results cheaper than in the hospital does it by itself. 
In the founder’s words Unipharma is “a B2B and B2G marketing company that 
commercializes and distributes pharmaceutical products”. In one word, Pedro calls the 
company an “auxiliary”. Unipharma was created in order to streamline the process of 
procurement, acquisition and distribution of unlicensed drugs. Just like e-bay or 
Amazon, with the appropriate limitations, of course, Unipharma brought suppliers and 
clients together, as an intermediate in the supply chain, smoothing the buying process. 
Unipharma enters in the definition of “market maker”, a company that buys, sells and 
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holds inventory, as opposed to a “broker” intermediary, the other type of supply chain 
intermediation that essentially deals with the provision of services without owning the 
goods being transacted (e.g., insurance agents, financial brokerage) (Resnick et al., 
1998). 
This intermediation process occurs when “a group of suppliers and buyers find 
beneficial to seek the service of a third party agent as an intermediary” and can be 
considered in two broad categories: transactional intermediaries and informational 
intermediaries (Shimchi-Levi, Wu and Shen, 2004). Unipharma can be placed within 
the definition of transactional intermediary as in general, these type of companies serve 
the following functions: 
 Reduce uncertainty by setting and stabilizing prices; 
 Reduce the costs associated with searching and matching; 
 Provide immediacy by holding inventory or reserving capacity; 
 Aggregate supply or demand to achieve economies of scale. 
Concluding, it is not unusual to see large multinationals displaying a high degree of 
vertical integration, participating in a broad range of activities that go from the early 
discovery to the distribution of a drug. This process comprises an enormous array of 
activities, including the development, manufacturing and quality control phases, which 
then evolve to the business stage, where the marketing, sales and distribution 
departments start operating. Nonetheless, for the reasons outlined during the case 
related to the SUAs, the Portuguese market was underserved which opened the window 
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2. Unipharma only sells products conceived for rare or uncommon 
conditions. How would you justify the attractiveness of a market with 
such low demand? Is the market still attractive? (Hint: The Porter’s 5 
Forces analysis may be useful.) 
(The time frame to answer this question should be around 20 minutes. It is important 
that the students clearly define the market for unlicensed drugs, using the concepts and 
frameworks learned during the theoretical classes. The class should come to the 
conclusion that given the actual circumstances the market is not attractive anymore.) 
The first thing that should be said is related to the first-mover advantage. Having moved 
beforehand any other company into a Blue Ocean (Kim and Mauborgne, 2005) 
Unipharma created a market space untainted by competition. The company created 
demand gathering all the interested hospitals and joining their needs. This first-mover 
advantage can be proved looking at present market shares where Idis and Unipharma 
(which entered the market as a sole company) are the leaders, with 50% and 30%, 
respectively. 
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In addition, a Porter’s 5 forces analysis may help to assess the attractiveness of the 
market. The guidelines which are considered relevant are provided below: 
Figure 7. Porter’s Five Forces Analysis 
Threat of new entrants (Low) 
 
- The main drugs in this segment are being sold 
by Unipharma or Idis and new drugs are not 
invented every day. 
- Operating with few products and with few 
hospitals becomes difficult to be competitive in 
prices and with short delivery times. Hospital 
may prefer to do the business themselves. 
- Threat of pharmaceutical companies entering 
on their own. 
- The strict legislation regulated by Infarmed 
Bargaining power of customers (Medium) 
 
- Hospitals know they have the alternative to 
contact the pharmaceutical companies 
themselves, therefore, the possibility to push 
prices up is reduced. 
- On the other hand, hospitals also know that 
this system increases their efficiency never 
taking the risk of running out of stock. 
- Hospitals may be interested in paying a 
premium for this service since they can always 
allocate the cost to the real final consumer, the 
patient. 
- The switching costs are low 
Threat of substitute products (Low) 
 
- There are, indeed, perfect substitutes, 
nevertheless, some of the companies producing 
them may not comply with the stringent 
Infarmed legislation and therefore the SUA is 
not accepted. 
Bargaining power of suppliers (Medium) 
 
- Most of these drugs do not have a patent, 
therefore, there is more than one company 
producing them 
- Buying in bulk gives some bargaining power 
to Unipharma regarding prices 
Rivalry among existing firms 
(Medium-Low) 
- The rivalry comes in obtaining 
products that are not being 
commercialized in Portugal yet. 
In this item, Unipharma may be 
in disadvantage due to Idis 
international nature. 
 
CATÓLICA-LISBON School of Business & Economics 
Manuel Coimbra  40 
The overall conclusion is that the market is not attractive at all for new entrants which 
decide to offer this type of services because now the Ocean is turning Red. In the short-
run, the prognosis is that Unipharma and Idis will continue in dispute for market share 
leadership and smaller companies, which do not compete directly with the big players 
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3. What should be, in your opinion, the value proposition of Unipharma? 
(In this simple question, planned for 10 minutes, it is intended that 2 or 3 students come 
up with a value proposition which states the most important points that characterize 
Unipharma, reason why the class should come to an answer to about the competitive 
advantage of the company.) 
“Strategy is based on a differentiated customer value proposition. Satisfying customers 
is the source of sustainable value creation.” (Kaplan and Norton, 2004) 
In this case, the creation of value to customers, the hospitals, is based in four pillars, 
which are also the factors that concede Unipharma competitive advantage: 
 The simplification of the acquiring process reducing the bureaucratic load; 
 The possibility to only buy the quantities needed and reduce stocks; 
 The decrease in delivering times increasing the response time; 
 The fact that, although there is one more player at the supply chain, the prices 
can be lowered. 
These four pillars support the two most important strategic objectives of any hospital, 
public or private, the improvement of the service increasing the patient welfare, which 
spends less time waiting for the drug, and the cost reduction. 
In turn, the attainment of these objectives is due to the differentiated service and the low 
prices Unipharma practices. 
Table 12. Strategic Matrix 
Source: Freire, A. (1997) “Estratégia: Sucesso em Portugal”, Editorial Verbo, Lisboa 
This competitive advantage can be considered as Differentiation with low cost 
leadership. It not also increased the market, allowing several hospitals to gain access to 
  Competitive advantage 













High Pure Differentiation 
Differentiation with low cost 
leadership 
Low No advantage Pure low cost leadership 
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many unlicensed drugs that were before unreachable, but also decreased prices 
substantially since it first begun. This resulted in hospitals getting their necessities close 
to 100%. 
Based on these facts, one example for a value proposition using the template proposed 
by Geoff Moore (1991) would be: 
For hospitals that have difficulties in buying unlicensed drugs, our service comprises all 
the steps of the process getting the drug to the final destination in a maximum of 48 
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4. In your opinion, what type of innovation does Unipharma stand for? 
Incremental or Disruptive? 
(This question requires some knowledge on innovation courses. It is meant to alert the 
students that a disruptive innovation does not directly imply a disruptive technology, 
since there are other factors that come into the equation. In this case, it is clear that with 
a technology far from being disruptive or even incremental, Unipharma created a new 
market through a disruptive strategy. 20 minutes are recommended so that the instructor 
can explain the relevant the concepts, if necessary.) 
The answer to this question is not straightforward since both answers can be accepted if 
well-founded. In order to get an accurate analysis, the suggestion is to breakdown the 
company into three areas and look at them separately: 
a) The technology 
b) The business plan 
c) The strategy 
As stated by Christensen (2003), “Disruptive technologies bring to a market a very 
different value proposition than had been available previously, Generally, disruptive 
technologies underperform established products in mainstream markets. But they have 
other features that a few fringe (and generally new) customers value”. Looking at a term 
in a broader way, it is possible to apply it not only to a technology but to innovation in 
general, whether it is a technology, a product or a service. Opposed to this type of 
innovation, there is the incremental or sustaining innovation, a type of innovation that 
does not create new markets or value networks but improves the existing ones 
(Christensen, 1997). 
Taking into account these definitions, one can conclude that regarding the technology 
there is not a clear degree of innovation present, at least for now, and that the business 
plan results as an incremental innovation of what was being done by the hospitals. What 
is disruptive in this company is the strategy, the way they changed the paradigm of the 
industry. Unipharma created a new market and changed the fundamentals of the 
business. Some reasons can be appointed to the success of the disruptive strategy: 
 The founders were both experienced managers in the industry 
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 Unipharma rearranged the process of acquisition, keeping to itself the tedious 
parts, making the purchase simpler and  more pleasant for the hospitals 
 Unipharma provided purchase motivators (the services included and the prices) 
 Adoption barriers like switching costs or unavailability of the products were not 
present 
 The word-of-mouth together with the personal presentation from hospital to 
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5. Considering that the SUA market in Portugal is not growing any further 
what do you suggest for the future? Should the company engage in an 
internationalization strategy? Should it expand its portfolio? (Hint: a 
SWOT analysis may be a useful tool to answer this question) 
(This is the question that gives more freedom for personal interpretation. As it is an 
intuitive question rather than quantitative one, the instructor should allow students to 
discuss it for some minutes. After this period, the instructor should intervene providing 
some additional input that may be useful in the analysis. 25 minutes should, at least, be 
saved for this question.)  
The best framework to predict the challenges Unipharma will face in the future is the 
SWOT analysis. According to Adriano Freire (1997), for a good strategist there are no 
threats since an apparent threat can be turned into a new opportunity. Therefore, 
companies must strengthen their competencies in order to take full advantage of 
windows of opportunity in the appropriate timing. In accordance, the new SWOT 
analysis replaces Threats with Time to better frame the strategic suggestions for the 
company. 
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Table 13. New SWOT Analysis 
 OPPORTUNITIES & TIME 
 
Short term Medium-long term 
 National market decreasing 
 Product volatility 
 Brazil as a pharmerging 
country 
 New EU countries 
investing in health 
 Decreasing bargaining 
power of pharmaceutical 
companies 
STRENGHTS  Decrease bureaucracy 
 Internationalize through 
spot exports to Spain, 
Angola, Brazil 




 Internationalize through 
spot exports and direct 
investment to Spain, Brazil, 
new EU countries 
 Develop an online platform 
to help in the stock 
management among 
hospitals 
 Service Quality 
 Delivery Time 
 Strong name 
 Competitive prices 
 Stock management 
 
WEAKNESSESS 
 Strategic alliances with 
Portuguese smaller 
companies 
 Expand  the company 
structure in order to keep 
up with the company 
growth 
 
 Expand portfolio with MA 
products 
 Risk of acquisition by an 
international company 
 Develop a software to 
make a personalized 
management 
 Strategic alliances with 
international players 
 Small structure 
 Difficulties in 
obtaining original 
documents 
 Inexistence of any 
alliance with other 
companies 
 Undiversified portfolio 
(only unlicensed) 
 
For 2013, internationalization is on the agenda. Starting by Spain, due to vicinity, and 
Brazil and Angola, due to cultural ties, the plan seems robust, though dare. Certainly the 
good relations with the suppliers and the “know-how” in the industry will play crucial 
roles, nevertheless, one must not forget that knowing in-depth the market is also 
important. In the short term, maybe an approach through transactions only is safer. 
Suggestions are the Spot Exports and the Exports through agents. 
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At a longer run, other opportunities arise. Regarding internationalization the new UE 
countries must be considered due to the investments taking place in the health sectors 
and to the nonexistence of such type of service on those countries. At that time, maybe 
direct investment start to make more sense, if they comply with the company strategy. 
Nonetheless, it is important that, before, the company expands its structure so these 
actions are in line with the company size.  
As regards to the portfolio management, this is a case where the BCG matrix does not 
apply so well due to the high volatility of the market, which increases the uncertainty 
regarding the products per se. This means that there are no such things as Cash Cows 
since one product that one year sells, for instance, 10000 units, can on the following 
year sell as much as 100 units, or vice-versa. Naturally, this does not apply for every 
product. For example, Antituberculostatics have a high demand every year due to the 
prevalence of HIV, a disease that increases the odds of getting tuberculosis. 
Looking back over the past 5 years one can easily verify the volatility of the products 
and this is why it is extremely important to being constantly expanding the portfolio of 
unlicensed drugs. In addition, there is the belief that this market will start to grow 
eventually in the next few years, another reason to justify the relentless search for new 
drugs.  
Looking further into the future, expanding the portfolio with other type of drugs may be 
a profitable opportunity. The Ansoff matrix can help on this analysis: 
Table 14. Ansoff Matrix 
  Product 






Present Market penetration 
Product Extension 






Medium-Long Term Strategy 
 
The company should continue its product extension actions so they can offer a wider 
span of products to the hospitals. The following phase would be the market extension, 
maybe trying to convert those SUA drugs in MAs., so they can be available to more 
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people. Finally, the diversification strategy would be distributing drugs with the MA 
already available. 
All these opportunities seem very likely to happen in the future, as the company evolves 
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